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Objective. Cyclophosphamide (CYC) is used in clinical practice off- label for the induction of remission in childhood 
polyarteritis nodosa (PAN). Mycophenolate mofetil (MMF) might offer a less toxic alternative. This study was undertaken 
to explore the relative effectiveness of CYC and MMF treatment in a randomized controlled trial (RCT).
Methods. This was an international, open- label, Bayesian RCT to investigate the relative effectiveness of CYC 
and MMF for remission induction in childhood PAN. Eleven patients with newly diagnosed childhood PAN were 
randomized (1:1) to receive MMF or intravenous CYC; all patients received the same glucocorticoid regimen. The 
primary end point was remission within 6 months while compliant with glucocorticoid taper. Bayesian distributions 
for remission rates were established a priori for MMF and CYC by experienced clinicians and updated to posterior 
distributions on trial completion.
Results. Baseline disease activity and features were similar between the 2 treatment groups. The primary end point 
was met in 4 of 6 patients (67%) in the MMF group and 4 of 5 patients (80%) in the CYC group. Time to remission was 
shorter in the MMF group compared to the CYC group (median 7.1 weeks versus 17.6 weeks). No relapses occurred 
in either group within 18 months. Two serious infections were found to be likely linked to MMF treatment. Physical 
and psychosocial quality- of- life scores were superior in the MMF group compared to the CYC group at 6 months and 
18 months. Combining the prior expert opinion with results from the present study provided posterior estimates of 
remission of 71% for MMF (90% credibility interval [90% CrI] 51, 83) and 75% for CYC (90% CrI 57, 86).
Conclusion. The present results, taken together with prior opinion, indicate that rates of remission induction in 
childhood PAN are similar with MMF treatment and CYC treatment, and MMF treatment might be associated with 
better health- related quality of life than CYC treatment.
INTRODUCTION
Polyarteritis nodosa (PAN) is a necrotizing vasculitis that 
causes aneurysmal nodules of medium- sized arteries (1,2). 
Childhood PAN is exceptionally rare, with a prevalence of ~1 per 
1 million children (1,3). Peak onset of childhood PAN is at age 7– 11 
years, with no sex bias (4,5). Features of childhood PAN include 
constitutional symptoms, vasculitis rash, myalgia, abdominal pain, 
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and arthropathy; however, any organ system can be affected 
(2,4,5). The etiology of childhood PAN remains unknown (6,7). 
In 2014, a monogenetic form of childhood PAN caused by defi-
ciency of adenosine deaminase 2 (DADA2) was described (8– 11).
If left untreated, the mortality rate of childhood PAN was his-
torically close to 100% within months of disease onset (12,13); 
with aggressive immunosuppression, the mortality rate is as low 
as 4% (4). Cyclophosphamide (CYC) has been used off- label for 
over 40 years in the treatment of PAN (14– 17) and is still recom-
mended for induction of remission in childhood PAN, though this 
has never been studied in a pediatric randomized controlled trial 
(RCT) (12). If alternative treatment exists, it is desirable that CYC 
treatment in children be avoided, since adverse reactions associ-
ated with CYC include infertility and malignancy (18).
Mycophenolate mofetil (MMF) is an alternative immunosup-
pressant with lymphocyte selective suppressive effects, which is 
associated with remission rates similar to those observed with 
CYC in the treatment of lupus nephritis (19) and antineutrophil 
cytoplasmic antibody (ANCA)– associated vasculitis (AAV) (20). 
MMF is not associated with urothelial malignancy or infertility and 
is used off- label in pediatric patients.
We hypothesized that MMF may be noninferior to CYC for 
induction of remission in childhood PAN and may be a less toxic 
alternative. Therefore, the purpose of the present study was to 
investigate the relative effectiveness of MMF and CYC for remis-
sion induction in childhood PAN. It is infeasible to conduct a con-
ventional, definitive phase III study of childhood PAN due to its 
rarity. We therefore opted for a Bayesian approach to assess the 
relative efficacy of MMF and CYC. This was a 2- stage process. 
Stage 1 consisted of a robust 2- day elicitation process conducted 
to quantify clinical opinion in light of results from a trial in adults 
(mycophenolate mofetil versus cyclophosphamide for remission 
induction in ANCA- associated vasculitis [MYCYC]) (20). The 
results from this trial were previously published (21). Stage 2 was 
a multicenter, open- label RCT of mycophenolate mofetil versus 
cyclophosphamide for the induction of remission of childhood 
PAN (the MYPAN trial; http://www.mypan.org.uk), and these data 
were used to further quantify the relative effectiveness of each 
treatment for remission induction in patients with newly diagnosed 
childhood PAN.
PATIENTS AND METHODS
Study design and patients. MYPAN was an interna-
tional multicenter, open- label, randomized controlled prospec-
tive trial comparing MMF treatment with intravenous (IV) CYC 
treatment for the remission of childhood PAN (Figure 1). The 
trial was sponsored by University College London, and the trial 
was coordinated and data were stored by the Liverpool Clini-
cal Trials Centre (LCTC) at the University of Liverpool. Centers 
were identified among members of the Paediatric Rheumatol-
ogy International Trials Organisation (PRINTO) (www.printo.it) 
(22).The trial was conducted using a Bayesian noninferiority 
design (noninferiority margin 10%). Children were randomized 
1:1 to receive either MMF (1,200 mg/m2/day, maximum 1 
gm twice daily) (12,23) or a standard IV CYC regimen (12). 
Randomization was achieved using a secure web- based tool 
generated centrally by the LCTC. Minimization variables for 
randomization were planned additional therapy with meth-
ylprednisolone >15 mg/kg at trial entry (yes/no) and plasma 
exchange at trial entry (yes/no). Treatment allocation prior to 
randomization was concealed from recruiting clinicians. Both 
trial groups received the same glucocorticoid treatment regi-
men per study protocol. The full protocol is available in Sup-
plementary MYPAN protocol V4.0 (available on the Arthritis & 
Rheumatology website at http://onlin elibr ary.wiley.com/doi/ 
10.1002/art.41730/ abstract).
Inclusion criteria were age at screening ≥4 years and ≤18 
years, new- onset childhood PAN (within 3 months of screening) 
classified in accordance with the European Alliance of Associa-
tions for Rheumatology/PRINTO/Paediatric Rheumatology Euro-
pean Society criteria (2,24), active vasculitis of any major organ, 
or meeting ≥3 minor components of the Pediatric Vasculitis Activ-
ity Score (PVAS) criteria (25) (see Supplementary Table 1, avail-
able on the Arthritis & Rheumatology website at http://onlin e  
libr ary.wiley.com/doi/10.1002/art.41730/ abstract).
Children were excluded if they did not meet the classification 
criteria for childhood PAN, if they received alternative diagnoses, if 
they had chronic infection, if they experienced previous reactions 
to one of the study medications, or if they had immunodeficiency 
or malignancy. Genetic screening for ADA- 2 was administered 
as part of the routine evaluation of the patients (i.e., outside the 
protocol).
Ethics approval. The protocol was approved by the 
Multicentre Research Ethics Committee in the UK and from 
relevant ethics committees for each participating center inter-
nationally. The study was conducted in accordance with the 
ethics principles of the Declaration of Helsinki. Patient and 
public involvement informed the design of the protocol and 
patient- facing trial documents. All participants provided written 
informed consent.
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Treatments. Participants received oral MMF or IV CYC 
treatment for 18 months, which comprised 3– 6 months of induc-
tion therapy (1:1 randomization); followed by 12– 15 months of oral 
azathioprine (AZA) maintenance therapy (Figure 1). Both groups in 
the trial received tapering glucocorticoids (see below). Unless par-
ticipants had an allergy, prophylaxis with trimethoprim/sulfameth-
oxazole was required until week 24. Trial treatment ended after 
18 months.
MMF was administered to patients until disease remission 
was achieved at 3– 6 months. The starting dose was 600 mg/m²/
day (maximum 1 gm/day) for the first week, followed by 1,200 mg/
m²/day (maximum 2 gm/day) in 2 divided doses (12,23,26).
CYC was administered at weeks 0, 2, and 4 and then every 
3 weeks until remission was achieved (maximum 10 IV doses 
and minimum 6 doses) (Supplementary Table 2, available on the 
Arthritis & Rheumatology website at http://onlin elibr ary.wiley.com/
doi/10.1002/art.41730/ abstract). The first dose was 500 mg/m2/
day, followed by 750 mg/m2/day (maximum dose 1.2 gm) (12). 
Mesna and IV fluids were administered, as per local practice. 
CYC could be discontinued after a minimum of 6 doses if disease 
was in remission. Patients were administered oral AZA (2 mg/kg/
day, maximum 200 mg/day) (12,26) the day following discontin-
uation of MMF treatment or 10– 14 days after the last dose of IV 
CYC.
All patients received prednisolone starting at 1 mg/kg/day 
(maximum 80 mg dose), which was decreased to 0.1 mg/kg/day 
by 6 months and to 0.05– 0.075 mg/kg by 9 months (Supplemen-
tary Table 3, available on the Arthritis & Rheumatology website 
at http://onlin elibr ary.wiley.com/doi/10.1002/art.41730/ abstract). 
Intravenous methylprednisolone could also be administered at 
trial entry (maximum 30 mg/kg for 3 doses or 3 gm total) at the 
investigator’s discretion.
Principal investigators recorded medications received by the 
patient on a medication clinical research form during protocol 
face- to- face follow- up trial visits as specified below. In addition, 
patients completed a diary listing the medications taken as an 
outpatient, which allowed careful cross- checking of the accuracy 
of medications taken on a daily basis.
Assessments. Assessments were performed at weeks 0, 
4, 10, 16, and 24 when the primary end point of remission was 
evaluated. Thereafter, assessments occurred at weeks 36, 48, 60, 
and 72. A final follow- up visit also took place on the date of the last 
patient’s last visit, which varied considerably among the patients. 
Therefore, only results up to and including week 72 are reported 
here.
Disease activity was determined using the PVAS (25). Briefly, 
the PVAS ranges from 0 to 63, with higher scores denoting active 
clinical disease activity within 9 organ systems and a score of 
0 indicating the absence of disease activity. Safety events were 
coded using The Medical Dictionary for Regulatory Activities 
 version 19.
Primary outcome measure. The primary outcome mea-
sure was remission within 6 months, which was defined as the 
absence of disease activity (PVAS 0 [of a maximum 63]) on 2 con-
secutive visits at least 1 month apart, with adherence to gluco-
corticoid taper protocol (20,21,25). The primary end point was 
assessed at 6 months because this reflects the typical time point 
to assess the effectiveness of remission induction in routine clinical 
practice (12) and is therefore used in most vasculitis  trials (20). 
Secondary end points assessed over the full 18- month trial were 
as follows: remission within 6 months regardless of glucocorti-
coid taper; time to remission; pediatric vasculitis damage index 
(PVDI) score (27,28); mycophenolic acid 12- hour trough levels; 
the cross- culturally adapted and validated version of the Child-
hood Health Assessment Questionnaire (C- HAQ) for disability and 
the Child Health Questionnaire (CHQ) for quality of life (29); cost- 
effectiveness using the UK NHS costs and quality- adjusted life- 
years (QALYs) measurement based on the Child Health Utility- 9D 
(CHU- 9D) (30) and EuroQol- 5D- 3L (EQ- 5D- 3L) questionnaires 
Figure 1. Overview of mycophenolate mofetil (MMF) versus cyclo -
phosphamide (CYC) for the induction of remission of childhood 
polyarteritis nodosa (cPAN) (the MYPAN trial). PVAS = Pediatric 
Vasculitis Activity Score; PO = by mouth; IV = intravenous.
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(31); cumulative glucocorticoid dose; growth; disease relapse 
within 18 months; adverse events; withdrawal from trial due to 
drug intolerance; and mortality.
Statistical analysis. Sample size. A maximum target 
sample size of 40 was chosen pragmatically, as this was the larg-
est number feasible to recruit among PRINTO sites. A Bayesian 
approach is not restricted by small sample sizes and allows data 
to be combined with existing evidence. The larger the recruit-
ment, the greater the contribution of trial results to the totality of 
evidence, post– MYPAN trial. Bayesian sample- size calculations 
suggested that this would yield a power of 62% to ascertain 
noninferiority of the primary end point (32). The MYPAN trial was 
conducted using a Bayesian design due to the challenge of low 
participant numbers, given that childhood PAN is extremely rare. 
Bayesian power was therefore also calculated for smaller sample 
sizes (8 patients [41% power], 10 patients [52% power], and 12 
patients [53% power]).
Data analyses. Per the recommendation in the Consolidated 
Standards of Reporting Trials statement (33), reported results are 
from the intent- to- treat (ITT) population. Missing data were not 
imputed. The date at which the primary outcome was achieved 
was the first of the 2 consecutive visits in which the PVAS was 0. 
The primary outcome was examined using a Bayesian analysis. 
Bayes theorem was used to combine expert prior opinion with 
the MYPAN data to obtain posterior distributions for remission 
rates with CYC treatment (pC), remission rates with MMF treat-
ment (pM), and the log odds ratio of remission with MMF com-
pared to CYC (θ).
Full details of the primary outcome measure analysis meth-
ods were previously published (21,32). Briefly, noninferiority of 
MMF was defined as a Bayesian posterior probability of obtain-
ing remission within 6 months, within 10% (absolute difference) 
of CYC. Quantities of interest were pC, pM, and θ. Bayesian 
prior distributions for pC and pM were established during a prior 
elicitation workshop in September 2013 (before recruitment for 
the MYPAN trial began), using expert opinion and evidence pre-
sented from the MYCYC trial (20,21,32). The posterior distri-
butions for pC, pM, and θ were calculated and summarized 
by their modes, which reflected the most likely values for these 
quantities, and by 90% credibility intervals (90% CrIs), which 
quantified our certainty. We also calculated 2 posterior prob-
abilities, i.e., that the 6- month remission rate among patients 
taking MMF is noninferior to the 6- month remission rate among 
patients taking CYC (pM ≥ pC – 0.10) and that achievement 
of remission within 6 months is more likely to occur among 
patients taking MMF than among those taking CYC (pM > pC). 
All secondary outcome measures were analyzed descriptively 
Figure 2. Flow chart of patient recruitment, treatment allocation, and patient follow- up in patients receiving mycophenolate mofetil (MMF) 
versus cyclophosphamide (CYC) for the induction of remission of childhood polyarteritis nodosa (MYPAN trial).
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using frequentist statistics (i.e., number, median, and interquar-
tile range [IQR]), unless otherwise stated. Results were sum-
marized graphically using Kaplan- Meier curves, patient profile 
plots, and radar plots.
For each participant, total NHS costs associated with primary 
care, secondary care, and community care services, and medi-
cation use were measured over 18 months. This was based on 
resource use questionnaires completed by trial participants or 
their parents or guardians during clinic appointments, and via 
information from case report forms. Unit costs were obtained from 
standard NHS sources (https://impro vement.nhs.uk/resou rces/
natio nal- tarif f/). The estimation of preference weights for each 
health state was generated from patient responses to CHU- 9D 
questionnaires (30). QALYs were then computed by applying the 
trapezium rule to estimate the area under the curve. Second- year 
costs and QALYs were discounted at 3.5%. Differences between 
the MMF and CYC treatment groups in costs and QALYs were 
estimated by linear regression, with the per- patient cost (or per 
QALY) as the dependent variable and the treatment group as the 
only independent predictor. A nonparametric bootstrap analysis 
using 10,000 replicates was performed to assess the joint uncer-
tainty in mean costs and QALYs. The probability of each treatment 
being cost- effective was determined at the threshold of £20,000 
per QALY, which operates within the NHS (34) and in accordance 
with the National Institute for Health and Care Excellence guid-
ance (https://www.nice.org.uk/proce ss/pmg9/). Analyses were 
performed using R version 3.6.1 or SAS version 9.4.
RESULTS
Patients. Eleven patients with childhood PAN were enrolled 
from January 2014 to June 2018 from 5 of 13 international 
centers (Great Ormond Street Hospital [n = 3], Alder Hey Chil-
dren’s NHS Foundation Trust [n = 3], Hacettepe University Chil-
dren’s Hospital [n = 3], Royal Manchester Children’s Hospital 
[n = 1], and Hospital Sant Joan de Déu [n = 1]). The randomized 
treatment allocation is summarized in Figure 2. Six patients were 
randomized to receive MMF, and 5 patients were randomized to 
receive CYC. All 11 patients received their allocated treatment and 
were retained for the primary analysis; 1 patient withdrew from 
follow- up at 26 weeks. Baseline characteristics of the patients are 
provided in Table 1 and Supplementary Table 4 (available on the 
Arthritis & Rheumatology website at http://onlin elibr ary.wiley.com/
doi/10.1002/art.41730/ abstract).
Table 1. Characteristics of the patients in the MMF group and the CYC group at trial entry*
Characteristic
MMF group   
(n = 6)
CYC group   
(n = 5)
All patients   
(n = 11)
Age at randomization, median (IQR) years 10.8 (7.0, 12.1) 7.9 (6.7, 9.4) 12.1 (4.6, 15.5)
Male 3 2 5
Female 3 3 6
Ethnicity
White 6 4 10
Mixed 0 1 1
Height Z score, median (IQR) −0.7 (−1.2, 1.0) 0.2 (−0.1, 0.2) −0.1 (−0.7, 1.0)
Weight Z score, median (IQR) −1.3 (−2.7, −0.3) 1.3 (0.7, 2.3) - 0.2 (−1.5, 1.3)
eGFR (mL/min/1.73 m2), median (IQR) 128.4 (125.8, 152.0) 101.3 (99.6, 101.9) 113.0 (101.3, 129.0)
PVAS (maximum 63), median (IQR) 8.5 (7.0, 12.0) 7.0 (6.0, 9.0) 7.0 (6.0, 12.0)
Affected organ system†
General/constitutional 6 4 10
Cutaneous 3 3 6
Eyes 1 0 1
Abdominal 5 4 9
Renal 0 1 1
Nervous 2 2 4
CRP (mg/liter; RR <5 mg/liter), median (IQR) 14.7 (4.0, 47.4) 4.0 (4.0, 38.0) 8.0 (4.0, 47.4)
ESR (mm/hour; 0– 10 mm/hour), median (IQR) 28.5 (7.0, 63.0) 16.0 (14.0, 28.0) 16.0 (7.0, 63.0)
C- HAQ disability index, median (IQR) 1.5 (0.6, 1.8) 1.5 (0.3, 1.5) 1.5 (0.6, 1.8)
Total dose of IV methylprednisolone  
pre- randomization, mg/kg
4 3 7
Median (IQR) 59.7 (45.6, 291.6) 87.2 (17.3, 222.2) 73.2 (45.0, 222.2)
Plasma exchange pre- randomization 0 0 0
ADA- 2 genetic screening‡ 5 2 7
* Except where indicated otherwise, values are the number of patients. MMF = mycophenolate mofetil; CYC = cyclophosphamide; 
IQR = interquartile range; eGFR = estimated glomerular filtration rate; PVAS = Pediatric Vasculitis Activity Score; CRP = C- reactive 
protein; ESR = erythrocyte sedimentation rate; C- HAQ = Childhood Health Assessment Questionnaire; IV = intravenous; ADA- 2 = 
adenosine deaminase 2. 
† A full breakdown list of all PVAS items is provided in Supplementary Table 4 (http://onlin elibr ary.wiley.com/doi/10.1002/art.41730/ 
abstract). 
‡ Four patients declined genetic testing for deficiency of adenosine deaminase 2 (DADA2) (1 in the MMF group and 3 in the CYC 
group). DADA2 was excluded in all 7 patients in the MMF and CYC groups. 
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Findings for the primary outcome measure. Remission 
within 6 months of randomization occurred in 4 of 6 patients (67%) 
in the MMF group and 4 of 5 patients (80%) in the CYC group. 
The Bayesian posterior distributions for remission rates (modes) 
were 71% (90% CrI 51, 83) for MMF and 75% (90% CrI 57, 86) for 
CYC, and the odds ratio of remission within 6 months with MMF 
compared to CYC was 0.81 (90% CrI 0.40, 1.65) (Figures 3 and 4). 
The posterior probability that MMF is noninferior to CYC was 0.76, 
indicating that noninferiority is likely. Also, the posterior probability 
that the 6- month remission rate is higher in MMF than in CYC was 
0.31, indicating that MMF superiority is unlikely (Figure 3).
Findings for the secondary efficacy outcome 
measures. Remission and relapses. All patients adhered to the 
protocol for glucocorticoids; hence, remission within 6 months 
regardless of glucocorticoid taper was the same as that for the 
primary end point. Five patients in the MMF group exhibited 
remission within 18 months, at a median of 7.1 weeks (IQR 4.0, 
10.3; full range 4– 25.6). Remission was achieved in all patients 
in the CYC group within 18 months, at median of 17.6 weeks 
(IQR 6.0, 18.9; full range 4.4– 35.3) (Supplementary Figure 1, 
available on the Arthritis & Rheumatology website at http://onlin e 
libr ary.wiley.com/doi/10.1002/art.41730/ abstract). No relapses 
occurred in either group.
Vasculitis damage, glucocorticoid exposure, and mortality. 
The median PVDI score was 0 (of a maximum 72) for both groups 
at trial entry. The median PVDI score at trial end (18 months) 
was 0 (IQR 0, 1) in the MMF group and 2 (IQR 0, 3) in the CYC 
group (Supplementary Table 5, available on the Arthritis & Rheu-
matology website at http://onlin elibr ary.wiley.com/doi/10.1002/
art.41730/ abstract). There was no major growth disturbance in 
either group. At 18 months, the median height Z score was −1.0 
Figure 3. Bayesian primary outcome analysis results. MMF = mycophenolate mofetil; CYC = cyclophosphamide.
Prior and Posterior Beliefs
Parameter Mode 90% Credibility Interval
pM Probability of remission within 6 months of 
randomization, given that the treatment was MMF
Prior 71% (45%, 85%)
Posterior 71% (51%, 83%)
pC Probability of remission within 6 months of 
randomization, given that the treatment was CYC
Prior 74% (51%, 86%)
Posterior 75% (57%, 86%)
θ Log-odds ratio of being in remission within 6 months, if 
given MMF compared with CYC 
Prior -0.17 (-0.91, 0.58)
Posterior -0.21 (-0.91, 0.50)
Exp (θ) Odds ratio of being in remission within 6 months, if 
given MMF compared with CYC
Prior 0.84 (0.40, 1.79)
Posterior 0.81 (0.40, 1.65)
Hypotheses Probability




Superiority Probability of superiority of MMF over CYC
Prior 0.356
Posterior 0.313
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(IQR −1.1, 1.0) in the MMF group and 0.0 (IQR −0.2, 0.1) in the 
CYC group, which were similar to heights at baseline. Cumu-
lative oral prednisolone doses at 6 and 18 months were simi-
lar between the 2 groups (Supplementary Table 6, available on 
the Arthritis & Rheumatology website at http://onlin elibr ary.wiley.
com/doi/10.1002/art.41730/ abstract). Three patients received 
IV methylprednisolone after randomization (1 patient in the CYC 
group and 2 in the MMF group). No patients died in either group.
Disability. Patients in both groups had moderate disability 
at baseline, but patients with moderate disability in the MMF 
group improved over time (Supplementary Table 7, available 
on the Arthritis & Rheumatology website at http://onlin elibr ary.
wiley.com/doi/10.1002/art.41730/ abstract). The median dis-
ability score (C- HAQ) at 18 months among patients with child-
hood PAN was 0 (of a maximum 3) (IQR 0, 0) in the MMF group 
and 1.0 (IQR 0.2,1.8) in the CYC group. C- HAQ pain scores 
decreased more rapidly in the MMF group compared to the CYC 
group (Supplementary Table 8, available on the Arthritis & Rheu-
matology website at http://onlin elibr ary.wiley.com/doi/10.1002/
art.41730/ abstract). Similarly, C- HAQ general assessment scores 
also improved more rapidly in the MMF group compared to the 
CYC group (Supplementary Table 9, available on the Arthri-
tis & Rheumatology website at http://onlin elibr ary.wiley.com/
doi/10.1002/art.41730/ abstract).
Quality of life. Results from the CHQ showed that quality of 
life was overall better in patients treated with MMF compared to 
those treated with CYC (Supplementary Table 10 and Supple-
mentary Figures 2– 4, available on the Arthritis & Rheumatology 
website at http://onlin elibr ary.wiley.com/doi/10.1002/art.41730/ 
abstract). At baseline, median CHQ physical summary scores 
reflected severe impairment in both groups, ~5 SD below the 
normal for a healthy control (8.3 [IQR −0.4, 18] in the MMF group 
and 9.0 [IQR 1.8, 14.0] in the CYC group). Similarly, median psy-
chosocial summary scores reflected impairment in both groups, 
though to a lesser degree than the physical summary scores 
(34.9 [IQR 32.5, 48.1] in the MMF group and 28.9 [IQR 25.0, 
32.7] in the CYC group). Physical summary scores and psy-
chosocial summary scores improved more rapidly and to an 
overall greater level in the MMF group compared to the CYC 
group (Supplementary Table 10 and Supplementary Figures 2– 4, 
available on the Arthritis & Rheumatology website at http://onlin e 
libr ary.wiley.com/doi/10.1002/art.41730/ abstract).
Health economics. The mean total discounted costs were 
£4,725 (95% confidence interval [95% CI] 1,480, 7,157) in 
the CYC group and £6,071 (95% CI 640, 15,555) in the MMF 
group. Participants in the CYC group experienced discounted 
QALYs of 1.18 (95% CI 1.07, 1.48), compared to 1.13 (95% 
CI 0.58, 1.44) in the MMF group. Therefore, MMF was more 
costly (£1,346 [95% CI −4709, 11,175]) and was associated 
with fewer QALYs (0.047 [−0.5749, 0.4798]) compared to 
CYC. The probability of MMF being cost- effective at a thresh-
old of £20,000 per QALY was 0.32, which was evaluated in the 
7 patients from the UK only.
Safety outcome measures. Total adverse events were 
similar between the 2 groups. Thirty- eight events (63% mild sever-
ity and 37% moderate severity) occurred in 5 of 6 patients treated 
with MMF, and 31 events (97% mild and 3% moderate) occurred 
Figure 4. Graphs showing prior and posterior distributions for mycophenolate mofetil (MMF) 6- month remission rate (A), cyclophosphamide 
(CYC) 6- month remission rate (B), and log odds ratio of 6- month remission if given MMF compared to CYC (C), and posterior distributions 
for MMF and CYC 6- month remission rates (D). MYPAN = mycophenolate mofetil versus cyclophosphamide for the induction of remission of 
childhood polyarteritis nodosa (trial).
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in all 5 patients treated with CYC (Table 2 and Supplementary 
Table 11, available on the Arthritis & Rheumatology website at 
http://onlin elibr ary.wiley.com/doi/10.1002/art.41730/ abstract). A 
total of 4 serious adverse events, including 2 infections, occurred in 
3 of 6 patients in the MMF group. One patient had abdominal pain 
(deemed not related to MMF) and a lower respiratory tract infection 
(possibly related to MMF), which fully resolved with treatment. One 
patient had colitis (deemed not related to MMF) ongoing at trial 
end, and 1 patient had herpes zoster (possibly related to MMF), 
which fully resolved with treatment. No serious adverse events 
were observed in the CYC group (Supplementary Table 12, avail-
able on the Arthritis & Rheumatology website at http://onlin elibr ary.
wiley.com/doi/10.1002/art.41730/ abstract). No patients withdrew 
from the trial due to drug intolerance.
DISCUSSION
A major challenge in the study of rare diseases is conducting 
a clinical trial with sufficient power to inform best clinical prac-
tice when the anticipated sample size is small. Historically, this 
has been an insurmountable barrier in the study of rare pedi-
atric autoimmune diseases, and explains why a clinical trial of 
childhood PAN had never been undertaken until now (21). We 
adopted a Bayesian clinical trial design with the objective of 
quantifying disease remission rates with CYC and MMF treat-
ment, combining a robust elicitation of prior opinion and evidence 
with our trial data. Six- month remission rates observed in the 
MYPAN trial were consistent with prior opinions, and since we 
could only recruit 11 patients, the totality of evidence is heavily 
influenced by those prior distributions. We calculated a Bayesian 
posterior probability of 76% for noninferiority of MMF compared 
to CYC for remission within 6 months. This observation, while 
not definitive, is still clinically useful, particularly since conducting 
a confirmatory frequentist trial is impossible (21). Further clinical 
face validity for the noninferiority of MMF compared to CYC is 
suggested by the fact that glucocorticoid use could be success-
fully tapered in all patients and all patients had nearly identical 
cumulative glucocorticoid exposure. Therefore, our results sug-
gest that MMF might represent a viable alternative to CYC for 
remission induction in childhood PAN. Moreover, these results 
will inform prior opinions for any future trials in childhood PAN 
(e.g., the Biologics in Refractory Vasculitis Study [https://www.
isrctn.com/ISRCT N1650 2655]).
The MYPAN data are consistent with data from studies in 
AAV, most notably the MYCYC study (20) (though not completely 
independently, as the MYCYC data helped inform the prior opin-
ion used in MYPAN), which included adults and children and 
showed that MMF was noninferior to CYC for inducing remission. 
Following remission, all patients in our trial received AZA and glu-
cocorticoid maintenance therapy, with no relapses. This obser-
vation contrasts with findings in the MYCYC trial which showed 
that relapses occurred earlier and more frequently among patients 
in the MMF group (33%) compared to among those in the CYC 
group (19%) (20). Thus, the previous suggestion that relapses in 
childhood PAN are less common than in childhood AAV is sup-
ported by our results (1).
Other secondary end points are also potentially clinically rel-
evant, though the results are purely descriptive. Remission was 
exhibited at a median of 7.1 weeks among patients in the MMF 
group, compared to a median of 17.6 weeks in the CYC group. 
PVDI scores were lower in the MMF group, implying less dam-
age, although our trial was not powered to demonstrate statistical 
significance of this observation. PVDI scores (and in adults, VDI 
scores) are not weighted; hence, overall low numerical scores can 
still indicate severe damage in patients. Therefore, future studies 
are needed to further examine the potential clinical importance of 
this preliminary observation.
C- HAQ disability scores and pain scores at trial end were 
comparable among patients in both groups, though scores 
were numerically lower among patients in the MMF group. While 
we must be careful not to overinterpret this purely descriptive 
observation, a possible obvious explanation is that the C- HAQ 
score reflected a more rapid resolution of disease activity among 
patients in the MMF group, resulting in faster resolution of dis-
ability and pain. Similarly, and in accordance with this sugges-
tion, quality of life improved more rapidly and to a greater extent 
among patients in the MMF group compared to the CYC group, 
particularly in regard to the physical summary score. The health 
economic analysis in the UK suggested that MMF may gener-
ate fewer QALYs and may be more expensive than CYC, though 
Table 2. Summary of adverse events in the MMF group compared to the CYC group*
MMF group   
(n = 6)
CYC group  
(n = 5)















All 38 5 (83.3) 31 5 (100) 69 10 (90.9)
Mild 24 2 (33.3) 30 4 (80) 54 6 (54.5)
Moderate 14 3 (50) 1 1 (20) 15 4 (36.4)
All SAEs, no. 4 3 (50) 0 0 (0) 4 3 (27)
* MMF = mycophenolate mofetil; CYC = cyclophosphamide; SAEs = serious adverse events. 
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with a significant element of uncertainty. No patients died in either 
trial group. Lastly, remission was achieved in all the patients in the 
MMF group who completed follow-up.
There were no new safety signals for MMF or CYC. Notably, 2 
infections were considered to be possibly linked to MMF. Improved 
short- term safety with MMF was thus not demonstrated. How-
ever, long- term safety issues are probably of more importance and 
are not captured in our trial. The use of MMF along with a stan-
dard dose of glucocorticoids offers clear advantages over CYC in 
terms of fertility preservation in younger patients, and potentially 
lower malignancy rates later in life, which is of particular concern 
among pediatric patients (18,20).
Our trial has several notable strengths. To our knowledge, 
it is the first randomized trial in childhood PAN. Patients were 
recruited from regional tertiary centers; thus, the trial cohort was 
fully representative of the spectrum of disease in childhood PAN, 
as indicated by the extent of organ involvement observed. The 
study also included the use of standardized tools developed spe-
cifically for children with vasculitis to allow accurate classification 
of childhood PAN (35), and of disease activity and remission (using 
the PVAS) (24). Our study was also the first to record vasculitis 
damage prospectively using the PVDI, which to date has been 
only preliminarily used in retrospective studies (27,28).
The strengths of this trial should be viewed against its limita-
tions, notably, that the clinical trial evidence is based on a small 
sample size, augmented by a distillation of clinical experience in 
the form of prior distributions. However, the fact that the poste-
rior distributions we observed are largely consistent with prior 
expert opinions adds important clinical face validity to the con-
clusion, which must be based on the final Bayesian posterior 
distributions and may provide the prior distributions for future 
cumulative research of childhood PAN. In addition, MYPAN was 
not blinded, for purely practical reasons. Although glucocorti-
coid exposure was documented, glucocorticoid toxicity was not 
systematically captured using the glucocorticoid toxicity index 
(36). Only 7 of 11 patients were screened for DADA2 as part 
of their routine evaluation, which might have important implica-
tions for determining the efficacy of both MMF and CYC in child-
hood PAN (10,11). Health economic analyses were based on 
UK costs, and therefore may not apply uniformly in other coun-
tries (e.g., in Turkey, where MMF is more expensive than CYC). 
Our trial also did not address the possibility that higher doses of 
MMF might be even more efficacious. Regulatory approval for 
dose escalation was initially requested in the MYPAN trial, but 
not granted by competent authority since it was suggested that 
adverse effects might also increase with higher doses. Finally, 
generalizability to other ethnic groups was limited as 10 of 11 
patients in our trial were White.
In summary, MMF is probably noninferior to CYC for induc-
tion of remission in childhood PAN when combined with gluco-
corticoids. MMF may also be associated with better quality of life 
compared to CYC.
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